What potential risk reduction could be achieved with evolocumab treatment? A simulation based on observational data from a cohort of users in 10 European countries

K Ray K; I Bridges; E Bruckert; B van Hout; M Sibartie; G Villa

Conference Papers Year : 2020

What potential risk reduction could be achieved with evolocumab treatment? A simulation based on observational data from a cohort of users in 10 European countries

, , (1, 2) , , , (3)

1
2
3

K Ray K

Function : Author

I Bridges

Function : Author

E Bruckert

Function : Author

Service d' Endocrinologie

Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases

B van Hout

Function : Author

M Sibartie

Function : Author

G Villa

Function : Author

Università degli studi di Parma = University of Parma

Domains

Life Sciences [q-bio]

Maryse Guerin : Connect in order to contact the contributor

https://hal.sorbonne-universite.fr/hal-03970175

Submitted on : Thursday, February 2, 2023-4:04:43 PM

Last modification on : Thursday, February 15, 2024-3:00:09 PM

Dates and versions

hal-03970175 , version 1 (02-02-2023)

Identifiers

HAL Id : hal-03970175 , version 1

Cite

K Ray K, I Bridges, E Bruckert, B van Hout, M Sibartie, et al.. What potential risk reduction could be achieved with evolocumab treatment? A simulation based on observational data from a cohort of users in 10 European countries. European-Society-of-Cardiology (ESC) Congress, Aug 2020, Amsterdam, Netherlands. ⟨hal-03970175⟩

What potential risk reduction could be achieved with evolocumab treatment? A simulation based on observational data from a cohort of users in 10 European countries

Domains

Dates and versions

Identifiers

Cite

Export

Collections

Share